JSKN003 + KN026 + capecitabine + enlonstobart

This drug product is a **combination therapy** of four agents: - **JSKN003**: a biparatopic antibody-drug conjugate (ADC) targeting HER2, designed using the KN026 antibody backbone with a site-specific conjugation of a topoisomerase I inhibitor payload. It achieves anti-tumor activity by binding to HER2 on tumor cells, leading to internalization and intracellular release of its cytotoxic payload. - **KN026**: a HER2-targeting bispecific monoclonal antibody forming the antibody backbone of JSKN003, known to block both HER2 dimerization interfaces and inhibit HER2 signaling. - **Capecitabine**: an orally available prodrug of 5-fluorouracil (5-FU), a pyrimidine analog that inhibits DNA synthesis by targeting thymidylate synthase after tumor-selective activation, used widely in solid tumors such as colorectal, gastric, and breast cancer. - **Enlonstobart**: limited public information is available; based on name conventions and usage in experimental regimens, enlonstobart is likely a biologic agent (possibly a novel monoclonal antibody or fusion protein). This combination aims for synergistic anti-tumor efficacy in cancers characterized by HER2 expression or dependency, and is in clinical investigation particularly for **solid tumors**, such as breast, ovarian, and gastrointestinal cancers. JSKN003 and related agents were developed using Alphamab Oncology’s proprietary platforms[1][3][5][7].

Other names

capecitabine